



(Mⁱ)
MEDINTEL
 Enhancing The Value of Science



BEST OF ASCO[®]
 OFFICIALLY LICENSED

23RD TO 25TH JUNE 2023
 CONRAD, PUNE

AGENDA BOOKLET



Conference Managed by



Main Conference (Hall A)

12:00 pm to
1:00 pm

Lunch

1:00 pm to
1:50 pmAcademic Session 1 - GU Cancer
Chairpersons - Dr Hemant Tongaonkar & Dr Ganesh Bakshi

100-105

Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study

Dr Nilesh Dhamne

105-110

Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial

Dr Mangesh Mekha

110-115

Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design

Dr Sanjay MH

115-120

TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations

Dr Chakor Vora

120-150

Panel Discussion
Moderator - Dr Vineet Talwar
Panelists - Dr Hollis D'Souza, Dr Amit Joshi, Dr Rahul Kulkarni, Dr Brijmohan Zanwar, Dr Vinayak Shenge, Dr Shailesh Shende, Dr Pushkar Ingle & Dr Bhalchandra Kashyapi

1:50 pm to
2:00 pm

Associated Meeting (Please refer to the Associated Meetings List)

2:05 pm to
2:15 pm

Associated Meeting (Please refer to the Associated Meetings List)

2:15 pm to
3:00 pmAcademic Session 2 - Gynaecological Cancer
Chairpersons - Dr Smita Gupte & Dr Snita Sinukumar

215-220

Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

Dr Amol Kotalwar

220-225

An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE)

Dr Jaipalreddy Pogal

225-230	Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up	Dr Mahesh Pawar
230-300	Panel Discussion Moderator - Dr Amita Maheshwari Panelists - Dr Chirag Desai, Dr Asma Pathan, Dr Sunit Lokwani, Dr Sushil Mandhaniya, Dr Sampada Dessai, Dr Sanjay Ahire, Dr Neeraj Dhingra, Dr Ravindra Mahajan & Dr Mansi Munshi	
3:00 pm to 3:20 pm	Associated Meeting (Please refer to the Associated Meetings List)	
3:20 pm to 3:40 pm	Associated Meeting (Please refer to the Associated Meetings List)	
3:40 pm to 4:30 pm	Academic Session 3 - Breast Cancer 1 Chairperson - Dr Sudeep Gupta	
340-345	Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer	Dr Udip Maheshwari
345-350	Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC)	Dr Atul Narayankar
350-355	Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH).	Dr Akash Jha
355-400	Randomized double-blind, placebo-controlled study of topical diclofenac in prevention of hand-foot syndrome in patients receiving capecitabine.	Dr Atul Batra
400-430	Panel Discussion Moderator - Dr TP Sahoo Panelists - Dr K Govind Babu, Dr Soumya Surath Panda, Dr Indoo Ammbulkar, Dr Bhagyashree Khaladkar, Dr Vinod Gore, Dr Pranjali Gadgil, Dr Swati Suradkar, Dr Rima Pathak & Dr Rohan Kharde	
4:30 pm to 4:50 pm	Associated Meeting (Please refer to the Associated Meetings List)	
4:50 pm to 5:10 pm	Associated Meeting (Please refer to the Associated Meetings List)	
5:10 pm to 5:30 pm	Associated Meeting (Please refer to the Associated Meetings List)	
5:30 pm to 5:50 pm	Associated Meeting (Please refer to the Associated Meetings List)	
5:50 pm to 6:40 pm	Academic Session 4 - Breast Cancer 2 Chairpersons - Dr Ramesh Nimmagadda & Dr NK Warriar	
550-555	Final overall survival (OS) analysis from the phase 3 TROPICS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC)	Dr Jayant Gawande

555-600	Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)	Dr Kripa Bajaj
600-605	An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02 and -03	Dr Suparna Rao
605-635	<p>Panel Discussion Moderator - Dr T Raja Panelists - Dr Vashishth Maniar, Dr Ghanashyam Biswas, Dr Ashish Singh, Dr Sachin Hingmire, Dr Amit Parasnis, Dr Navin Kasliwal, Dr Anupama Mane, Dr Bhooshan Zade, Dr Vaishali Shinde & Dr Chandrashekhar Tamane</p>	
6:35 pm to 6:45 pm	Associated Meeting (Please refer to the Associated Meetings List)	
6:45 pm to 6:55 pm	Associated Meeting (Please refer to the Associated Meetings List)	
6:55 pm to 7:05 pm	Associated Meeting (Please refer to the Associated Meetings List)	
7:05 pm to 7:15 pm	Associated Meeting (Please refer to the Associated Meetings List)	
7:15 pm to 8:00 pm	Academic Session 5 - CNS	
715-720	INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.	Dr Shruti Gandhi
720-725	Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses	Dr Fahad Afzal
725-730	External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma	Dr Prakash Devde
730-735	Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study	Dr Aditya Sarin
735-800	<p>Panel Discussion Moderator - Dr Vijay Patil Panelists - Dr Bhavesh Parekh, Dr Gaurav Nigade, Dr Kripa Bajaj, Dr Vikas Kothavade, Dr Rahul Krishnatry, Dr Tejpal Gupta, Dr Chandrashekhar Raman & Dr Taher Chharchhodawala</p>	
8:00 pm onwards	Dinner	

Main Conference (Hall A)

9:00 am to 9:50 am		Academic Session 6 - GI Cancer 1 (Colorectal) Chairperson - Dr Ajay Jadhav	
900-905	PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).	Dr Stalin Chowdary Bala	
905-910	Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial	Dr Shrinivas Kulkarni	
910-915	Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial	Dr Nitin Chaudhari	
915-920	HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS	Dr Tushar Mule	
920-950	Panel Discussion Moderator - Dr Prasad Narayanan Panelists - Dr Bhupesh Guleria, Dr Abhishek Anand, Dr Shravan Tungenwar, Dr Nagesh Sirsath, Dr Rakesh Neve, Dr Sujai Hegde, Dr Ajay Punpale, Dr Nilesh Chandak, Dr Sanjay MH & Dr Pramod Tike		
9:50 am to 10:10 am	Associated Meeting (Please refer to the Associated Meetings List)		
10:10 am to 10:30 am	Associated Meeting (Please refer to the Associated Meetings List)		
10:30 am to 11:15 am		Academic Session 7 - GI Cancer 2 (Non Colorectal) Chairpersons - Dr Girish Phadke & Dr Kamlesh Bokil	
1030-1035	A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.	Dr Sushma Agrawal	
1035-1040	A multicenter, open-label, randomized phase II study evaluating adjuvant gemcitabine plus cisplatin (GC) and capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenocarcinoma (GBC): The GECCOR-GB trial.	Dr Anant Ramaswamy	
1040-1045	Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial	Dr Salil Patkar	
1045-1115	Panel Discussion Moderator - Dr Nikhil Ghadyalpatil Panelists - Dr Prabhat Bhargava, Dr Devendra Pal, Dr Ritu Dave, Dr Vipul Doshi, Dr Sanket Bankar, Dr Ninad Gadekar, Dr Gajanan Kanitkar, Dr Amol Ubale, Dr Shweta Mutha, Dr Upasna Saxena & Dr Vijay Palwe		

11:15 am to 11:35 am	Associated Meeting (Please refer to the Associated Meetings List)	
11:35 am to 12:10 pm	Academic Session 8 - Bone & Sarcoma Chairpersons - Dr Shailesh Kanvinde & Dr Praful Rawate	
1135-1140	A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902)	Dr SP Shrivastava
1140-1145	Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE	Dr Anjana Sainani
1145-1210	Panel Discussion Moderator - Dr Manish Pruthi Panelists - Dr Prasanna Deshmukh, Dr Padmaj Kulkarni, Dr Amol Akhade, Dr Tanveer Maksud, Dr Dattatraya Andure, Dr Mishil Parikh, Dr Mani Gundavda, Dr Joy Ghose, Dr Mahesh Sambhus, Dr Madhu Sairam, Dr Dipalee Borade & Dr Sonali Pingle	
12:10 pm to 12:30 pm	Associated Meeting (Please refer to the Associated Meetings List)	
12:30 pm to 1:00 pm	Associated Meeting (Please refer to the Associated Meetings List)	
1:00 pm to 1:25 pm	Associated Meeting (Please refer to the Associated Meetings List)	
1:25 pm to 1:50 pm	Lunch	
1:50 pm to 2:40 pm	Academic Session 9 - Hemat (Lymphoma) Chairperson - Dr Kannan Subramanian	
150-155	SWOG S1826, a Randomized Study of Nivolumab (N) AVD versus Brentuximab Vedotin (BV) AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma	Dr Mubarakunnisa Tonse
155-200	Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma	Dr Pratik Patil
200-205	Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study	Dr Ravikumar Wategaonkar
205-210	Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance)	Dr Mukul Gharote
210-240	Panel Discussion Moderator - Dr Hemant Malhotra Panelists - Dr Chandrashekhar Pethe, Dr Hari Menon, Dr Akshay Shivchhand, Dr Ashish Joshi, Dr Vijay Ramanan, Dr Nilesh Wasekar & Dr Abhijit Baheti	
2:40 pm to 3:00 pm	Associated Meeting (Please refer to the Associated Meetings List)	
3:00 pm to 3:50 pm	Academic Session 10 - Hemat (Myeloma) Chairperson - Dr Shriram Kane	

300-305	First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PvD or DPd) in lenalidomide-refractory multiple myeloma	Dr Anant Gokarn
305-310	Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study	Dr Sonal Dhande
310-315	Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results	Dr Urmi Sheth
315-320	CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pre-treated patients with relapsed/refractory multiple myeloma	Dr Makarand Randive
320-350	<p>Panel Discussion Moderator - Dr Bhausaheb Bagal Panelists - Dr Sweta Lunkad, Dr Dayanand Upase, Dr Sameer Melinkeri, Dr Sandip Bartakke, Dr Chitresh Aggarwal, Dr Vishal Khaladkar, Dr Suhas Aagre & Dr Anil Singhvi</p>	
3:50 pm to 4:00 pm	Associated Meeting (Please refer to the Associated Meetings List)	
4:00 pm to 4:10 pm	Associated Meeting (Please refer to the Associated Meetings List)	
4:10 pm to 4:30 pm	Associated Meeting (Please refer to the Associated Meetings List)	
4:30 pm to 4:50 pm	Associated Meeting (Please refer to the Associated Meetings List)	
4:50 pm to 5:40 pm	Associated Meeting (Please refer to the Associated Meetings List)	
5:40 pm to 6:00 pm	Associated Meeting (Please refer to the Associated Meetings List)	
6:00 pm to 6:20 pm	Associated Meeting (Please refer to the Associated Meetings List)	
6:20 pm to 6:40 pm	Associated Meeting (Please refer to the Associated Meetings List)	
6:40 pm to 7:20 pm	Associated Meeting (Please refer to the Associated Meetings List)	
7:20 pm to 8:10 pm	Academic Session 11 - Lung Cancer 1 Chairperson - Dr Samir Gupta	
720-725	OS survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIa NSCLC	Dr Chetna Bakshi
725-730	MSH3 and MSH6 gene polymorphisms: Association with lung cancer susceptibility and prognostic value in patients with NSCLC undergoing platinum-based chemotherapy.	Dr Siddharth Sharma

730-735	IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial	Dr Kshitij Joshi
735-810	Panel Discussion Moderator - Dr Ullas Batra Panelists - Dr Chetan Deshmukh, Dr Ram Abhinav, Dr Mithun Shah, Dr Jacob George, Dr Ashish Pokharkar, Dr Shrikant Ankolikar, Dr Shishir Shetty, Dr Abhishek Shankar, Dr Jatin Bhatia & Dr Nilesh Mahale	
8:10 pm to 8:20 pm	Associated Meeting (Please refer to the Associated Meetings List)	
8:20 pm onwards	Dinner	

Day 3 | 25th June, 2023 | Sunday


Main Conference (Hall A)

9:00 am to 9:50 am	Academic Session 12 - Lung Cancer 2 Chairperson - Dr BK Smruti	
900-905	TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC)	Dr Minish Jain
905-910	Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study	Dr Bharat Patodiya
910-915	The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L)	Dr Bhavesh Poladia
915-950	Panel Discussion Moderator - Dr Amit Rauthan Panelists - Dr Shailesh Bondarde, Dr Ashish Bakshi, Dr Pushpak Chirmade, Dr Deepak Koppaka, Dr Amol Dongre, Dr Darshana Rane, Dr Anup Tamhankar, Dr Nagesh Madnoorkar & Dr Anil Tibdewal	
9:50 am to 10:40 am	Associated Meeting (Please refer to the Associated Meetings List)	
10:40 am to 11:30 am	Academic Session 13 - Head & Neck Cancer Chairpersons - Dr Anantbhusan Ranade & Dr Anil D'Cruz	
1040-1045	PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)	Dr Shruti Behal

1045-1050	Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.	Dr Ghanashyam Biswas
1050-1055	10-year outcomes of technically unresectable oral cancers with neoadjuvant chemotherapy: Real-world data and implications for clinical practice.	Dr Aditya Dhanawat
1055-1100	Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).	Dr Rushabh Kothari
1100-1130	<p>Panel Discussion</p> <p>Moderator - Dr Shyam Aggarwal</p> <p>Panelists - Dr Sunil Chopade, Dr S Krupa Shankar, Dr Rushabh Kothari, Dr Arvind Krishnamurthy, Dr Satish Sonawane, Dr Manish Bhatia, Dr Jagdish Shinde, Dr Sumit Goyal, Dr Trinanjan Basu & Dr Yash Devckar</p>	
11:30 am to 11:50 am	Associated Meeting (Please refer to the Associated Meetings List)	
11:50 am to 12:00 pm	Associated Meeting (Please refer to the Associated Meetings List)	
12:00 pm to 12:10 pm	Associated Meeting (Please refer to the Associated Meetings List)	
12:10 pm to 12:30 pm	Associated Meeting (Please refer to the Associated Meetings List)	
12:30 pm to 1:20 pm	Associated Meeting (Please refer to the Associated Meetings List)	
1:20 pm to 2:10 pm	Associated Meeting (Please refer to the Associated Meetings List)	
2:10 pm onwards	Lunch	

BEST OF ASCO®

OFFICIALLY LICENSED



Conference Managed by



WE THANK OUR SUPPORTERS



KEY CONTACT NUMBERS

Main Conference Hall (A) - Kartik Jhaveri: +91 99206 92323

Board Room (B) - Rahul Panikar: +91 93215 30354

Registration Desk - Soffiya Anthony Raj: +91 88982 32348

Travel & Accommodation - Himanshi Sharma: +91 88791 79898

Exhibition Stalls - Vinesh Murudkar: +91 84240 50884

Overall Coordination - Kashish Parikh: +91 98190 25850

Conference Managed by

